A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery

Phosphoinositides regulate many cellular processes, and cellular levels are controlled by kinases and phosphatases. SHIP2 (SH2 (Src homology 2)-domain-containing inositol-phosphatase-2) plays a critical role in phosphoinositide signaling, cleaving the 5-phosphate from phosphatidylinositol 3,4,5-tris...

Full description

Saved in:
Bibliographic Details
Main Authors: Persson, Camilla, Cozier, Gyles, Trésaugues, Lionel, Erneux, Christophe, Nordlund, Pär, Mills, Stephen J., Thomas, Mark P., Riley, Andrew M., Potter, Barry V. L.
Other Authors: School of Biological Sciences
Format: Article
Language:English
Published: 2013
Subjects:
Online Access:https://hdl.handle.net/10356/97967
http://hdl.handle.net/10220/12267
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-97967
record_format dspace
spelling sg-ntu-dr.10356-979672022-02-16T16:27:58Z A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery Persson, Camilla Cozier, Gyles Trésaugues, Lionel Erneux, Christophe Nordlund, Pär Mills, Stephen J. Thomas, Mark P. Riley, Andrew M. Potter, Barry V. L. School of Biological Sciences DRNTU::Science::Biological sciences Phosphoinositides regulate many cellular processes, and cellular levels are controlled by kinases and phosphatases. SHIP2 (SH2 (Src homology 2)-domain-containing inositol-phosphatase-2) plays a critical role in phosphoinositide signaling, cleaving the 5-phosphate from phosphatidylinositol 3,4,5-trisphosphate. SHIP2 is thought to be involved in type-2 diabetes and obesity, conditions that could therefore be open to pharmacological modulation of the enzyme. However, rational design of SHIP2 inhibitors has been limited by the absence of a high-resolution structure. Here, we present a 2.1 Å resolution crystal structure of the phosphatase domain of SHIP2 bound to the synthetic ligand biphenyl 2,3′,4,5′,6-pentakisphosphate (BiPh(2,3′,4,5′,6)P5). BiPh(2,3′,4,5′,6)P5 is not a SHIP2 substrate but inhibits Ins(1,3,4,5)P4 hydrolysis with an IC50 of 24.8 ± 3.0 μM, (Km for Ins(1,3,4,5)P4 is 215 ± 28 μM). Molecular dynamics simulations suggest that when BiPh(2,3′,4,5′,6)P5 binds to SHIP2, a flexible loop folds over and encloses the ligand. Compounds targeting such a closed conformation might therefore deliver SHIP2-specific drugs. 2013-07-25T07:25:39Z 2019-12-06T19:48:53Z 2013-07-25T07:25:39Z 2019-12-06T19:48:53Z 2012 2012 Journal Article Mills, S. J., Persson, C., Cozier, G., Thomas, M. P., Trésaugues, L., Erneux, C., et al. (2012). A Synthetic Polyphosphoinositide Headgroup Surrogate in Complex with SHIP2 Provides a Rationale for Drug Discovery. ACS Chemical Biology, 7(5), 822-828. https://hdl.handle.net/10356/97967 http://hdl.handle.net/10220/12267 10.1021/cb200494d 22330088 en ACS chemical biology © 2012 American chemical society.
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic DRNTU::Science::Biological sciences
spellingShingle DRNTU::Science::Biological sciences
Persson, Camilla
Cozier, Gyles
Trésaugues, Lionel
Erneux, Christophe
Nordlund, Pär
Mills, Stephen J.
Thomas, Mark P.
Riley, Andrew M.
Potter, Barry V. L.
A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery
description Phosphoinositides regulate many cellular processes, and cellular levels are controlled by kinases and phosphatases. SHIP2 (SH2 (Src homology 2)-domain-containing inositol-phosphatase-2) plays a critical role in phosphoinositide signaling, cleaving the 5-phosphate from phosphatidylinositol 3,4,5-trisphosphate. SHIP2 is thought to be involved in type-2 diabetes and obesity, conditions that could therefore be open to pharmacological modulation of the enzyme. However, rational design of SHIP2 inhibitors has been limited by the absence of a high-resolution structure. Here, we present a 2.1 Å resolution crystal structure of the phosphatase domain of SHIP2 bound to the synthetic ligand biphenyl 2,3′,4,5′,6-pentakisphosphate (BiPh(2,3′,4,5′,6)P5). BiPh(2,3′,4,5′,6)P5 is not a SHIP2 substrate but inhibits Ins(1,3,4,5)P4 hydrolysis with an IC50 of 24.8 ± 3.0 μM, (Km for Ins(1,3,4,5)P4 is 215 ± 28 μM). Molecular dynamics simulations suggest that when BiPh(2,3′,4,5′,6)P5 binds to SHIP2, a flexible loop folds over and encloses the ligand. Compounds targeting such a closed conformation might therefore deliver SHIP2-specific drugs.
author2 School of Biological Sciences
author_facet School of Biological Sciences
Persson, Camilla
Cozier, Gyles
Trésaugues, Lionel
Erneux, Christophe
Nordlund, Pär
Mills, Stephen J.
Thomas, Mark P.
Riley, Andrew M.
Potter, Barry V. L.
format Article
author Persson, Camilla
Cozier, Gyles
Trésaugues, Lionel
Erneux, Christophe
Nordlund, Pär
Mills, Stephen J.
Thomas, Mark P.
Riley, Andrew M.
Potter, Barry V. L.
author_sort Persson, Camilla
title A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery
title_short A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery
title_full A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery
title_fullStr A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery
title_full_unstemmed A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery
title_sort synthetic polyphosphoinositide headgroup surrogate in complex with ship2 provides a rationale for drug discovery
publishDate 2013
url https://hdl.handle.net/10356/97967
http://hdl.handle.net/10220/12267
_version_ 1725985704901607424